China's new coronavirus vaccine provides 5 vaccines free of charge to the whole people and enters phase III clinical trial

Five vaccines in China enter phase III clinical trials

At the press conference, Chen Shifei, deputy director of the State Drug Administration, said that Sinopharm's China Bio new crown inactivated vaccine had been approved by the State Drug Administration for conditional marketing. The existing data show that the protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, meeting the relevant standards of who and SFDA. In the future, the persistence and protective effect of the vaccine should be observed continuously.

In addition, Xu Nanping, Vice Minister of the Ministry of science and technology, said that so far, 14 vaccines from five technical routes have entered clinical trials in China, of which five vaccines from three technical routes have entered phase III clinical trials.

Grant of new vaccines in Beijing and Hubei
At the press conference, Chen Shifei said that the drug regulatory and inspection institutions in Beijing and Hubei Province have been awarded the task of issuing the new crown vaccine in batches. In accordance with relevant regulations and administrative measures, the batch issuing agency will strictly audit and inspect each batch of vaccines to ensure that each vaccine is qualified.

Does the new coronavirus mutation affect the efficacy of the vaccine?

At the press conference, Xu Nanping said that the scientific research team has held many meetings, and experts believe that there is no evidence that the new coronavirus mutation will have a substantial impact on the use of the vaccine, but it needs high attention.

What is the price of the approved vaccine?

Zeng Yixin, deputy director of the National Health Commission, said that the basic attribute of the new coronavirus vaccine is public goods, and the price will change according to the scale of use, but one major premise is definitely to provide free for all.

Over 3 million doses of the vaccine have been given to key population in China, with good safety
At the press conference, Zeng Yixin introduced the vaccination work of key groups of Xinguan vaccine. He said that China's vaccine research and development has always been the first in the world
Since the official launch of vaccination work for key population on December 15, the cumulative number of inoculations has exceeded 3 million.

The results of vaccination fully proved that the safety of vaccine in China was good, a certain proportion of adverse reactions occurred, and the total incidence was close to that of conventional inactivated vaccine.

The main performance is local pain, induration, mild fever rate is less than 0.1%, allergy and other serious situation is two parts per million, these situations after timely treatment are very good treatment.

Next, we will comprehensively promote the vaccination of the elderly and people with basic diseases, and then carry out the vaccination of other ordinary people. In the future, all the eligible people will be able to "receive as much as possible.".

Sinopharm China Biological New Crown inactivated vaccine has been approved by the State Food and Drug Administration for conditional listing

Vaccine research and development will never "rush" for the first place

At the press conference, Zheng Zhongwei, head of the working group of new crown vaccine research and development, said that the vaccine research and development process is a race against the virus, but we fully respect the scientific laws and principles of vaccine research and development.
China is the first to carry out clinical trials, and also the first to carry out phase III clinical trials. However, due to the good control of the epidemic situation in our country, we carry out clinical trials abroad, strictly abide by the relevant rules in the process of clinical trials, and will never "rush" for the first place.